BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SJ, Rhu J, Lee SH, Kim JM, Choi GS, Kim K, Joh JW. Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients. Ann Surg Treat Res 2020;99:180-7. [PMID: 32908850 DOI: 10.4174/astr.2020.99.3.180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhao T, Yang Z, Yu J, Lu J, Li L, Xu X, Cao H, Zheng S. Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients. Advanced Gut & Microbiome Research 2022;2022:1-9. [DOI: 10.1155/2022/4779960] [Reference Citation Analysis]
2 Yang X, Yan H, Zhang X, Qin X, Guo P. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: A Systematic Review and Meta-analysis. Int J Infect Dis 2022:S1201-9712(22)00519-7. [PMID: 36122671 DOI: 10.1016/j.ijid.2022.09.021] [Reference Citation Analysis]